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This perspective describes the motivation, development, and implementation of pathway-based content for My Cancer
Genome, anonlineprecisionmedicine knowledge resourcedescribingclinical implicationsof genetic alterations in cancer.
As researchers uncover more about cancer pathogenesis, we are learning more not only about the specific genes and
proteins involved but also about how those genes and proteins interact with others along cell signaling pathways. This
knowledge has led researchers and clinicians to begin to think about cancer therapy using a pathway-based approach. To
facilitate this approach, My Cancer Genome used a list of more than 800 cancer-related genes to identify 20 cancer-
relevant pathways and then created content focused on demonstrating the therapeutic relevance of these pathways.
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http://dx.doi.org/10.1016/j.tranon.2016.03.001Precision medicine has altered the standard of care for cancer
treatment and has led to the rapid development of therapies that
inhibit diverse cellular processes. As we learn more about cancer
pathogenesis, the number of plausible therapeutic targets increases.
Targeted therapies have evolved from the use of single agents that
inhibit a single gene effector to the use of one or more agents that
target multiple effectors in a single cell signaling pathway or multiple
effectors in parallel signaling pathways. As such, successful therapeutic
strategies are evolving from a single-gene/single-drug focus to a
pathway-based focus. This evolution of thought in targeted cancer
therapy is an opportunity to develop a pathway-oriented view of
cancer genomic knowledge resources. In response to this shift, the
team at My Cancer Genome, http://www.mycancergenome.org/ [1], a
project spearheaded at the Vanderbilt-Ingram Cancer Center, has
developed a pathway-based approach to education and knowledge
curation for precision cancer medicine.
Targeted therapies revolutionized cancer medicine by enabling
disease control in traditionally difficult to treat malignancies, such as
BRAF-mutated melanoma, by targeting the mutated gene with a
single inhibitor. As knowledge of cancer pathogenesis advanced, the
number of targeted therapies rapidly increased—making it essential to
understand the complex signaling networks through which alteredgenes function and interact to contribute to disease. Understanding
these signaling pathways will facilitate the creation of rational
combination therapies for cancer patients with the ultimate goal of
increasing the depth and duration of response. Two approaches to
pathway-based treatment strategies are vertical and parallel inhibition.
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Figure 1. Cancer-relevant pathway map. This figure depicts the names of the most cancer-relevant pathways onMy Cancer Genome and
their sites of action within the tumor cell. For example, the G-protein signaling pathway commences at the cell membrane and then
transduces downstream signals within the tumor cell. Individual pathway figures for each cell signaling pathway can be found on the My
Cancer Genome website at http://www.MyCancerGenome.org/content/pathways [6]. Reprinted, with permission, from My Cancer
Genome. Copyright 2016 Vanderbilt University.
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melanoma. Single-agent BRAF inhibition induced response rates in
53% of patients with BRAF-mutated melanoma [2]; however,
acquired resistance invariably developed in these tumors. This
therapeutic escape created a problem: how could clinicians extend
the drug response and delay or overcome acquired resistance? The
solution depends on understanding the complex interactions BRAF
maintains with other proteins in a cancer cell. By combining BRAF
with MEK inhibitors, two targets in the same pathway, clinicians can
extend the drug response [3]. This method of targeted cancer therapy
is known as vertical inhibition—simultaneously targeting multiple
proteins with multiple inhibitors within the same signaling pathway.
With vertical inhibition, clinicians may create stronger, on-target
inhibition of nodes in the same pathway.
To understand parallel inhibition, consider the example of ER+
breast cancer. In 2012, the aromatase inhibitor exemestane was FDA
approved for use in combination with mTOR inhibitor everolimus
for patients with ER+ metastatic breast cancer [4]. Exemestane targets
the hormone signaling pathway, whereas everolimus targets the PI3K/
AKT1/mTOR pathway. In 2015, the aromatase inhibitor letrozole
was FDA approved for use in combination with CDK4/6 inhibitor
palbociclib for postmenopausal patients with ER+, HER2-negative
advanced breast cancer [5]. Letrozole targets the hormone signaling
pathway, whereas palbociclib targets the cell cycle. This method oftargeted cancer therapy is known as parallel inhibition—simultaneously
targeting multiple nodes in different cell signaling pathways.
Currently available resources can provide a seemingly overwhelm-
ing amount of information regarding the complex entanglement of
upstream, downstream, and parallel signaling pathways involved in
the cellular circuitry. The complexity may make it difficult and time
consuming for a busy clinician to search for a given protein target of
interest. Furthermore, currently available resources may not be able to
easily connect the pathway information to information directly
pertaining to the therapeutic strategies. The team at My Cancer
Genome recognizes that keeping up with the rapid development of
targeted therapies amidst a busy clinical schedule is challenging;
therefore, the team has restructured typical complex signaling
pathways to be more digestible to clinicians in practice. The goal
was to create a resource from which a clinician would be able to
quickly glean the information necessary to understand the signifi-
cance of an individual pathway that drives cancer pathogenesis or a
therapeutic strategy within the context of precision cancer medicine.
The creation of a pathway-based resource for genomic information
reflects the emergence of combination therapies used in current
cancer treatment. The methodology behind the creation of the
pathway content focused on ease of understanding while maintaining
clinical relevance; the team aimed to create pathway diagrams that
were clinically applicable, gearing the level of information toward
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Genome editorial team to outline a map of the most cancer-relevant
pathways (Figure 1) [6]. We then categorized a master list of
approximately 820 cancer-related genes [7] compiled from several
commonly used next-generation sequencing cancer platforms. From
there, we created diagrams that were isolated from surrounding
pathway interactions. Each diagram included the most relevant
proteins in each pathwaywith a focus on therapeutic targets.Descriptive
text that defined each pathway’s function, activators, inhibitors, and
cellular outputs was created to accompany the pathway diagram. Each
figure includes a pathway summary describing the components of the
pathway, diseases in which the pathway is aberrantly activated, and a
drug list—all of which link tomore detailed informationwhere available
on the My Cancer Genome website.
A single-gene to single-drug approach was once the most effective
strategy in cancermedicine.However, diagnostic tools and cancer therapies
continue to advance, as do complex cancer mechanisms. With the
capability to identify multiple mutations within a tumor, clinicians will
benefit from understanding why and how to effectively inhibit multiple,
co-occurring genomic alterations within the tumor. A pathway-based
approach to cancer medicine may help clinicians find answers to hard
questions: Are the alterations related? Which genes do the altered genes
interact with? Are the alterations targetable? If so, do drugs exist that can
effectively inhibit each alteration?A pathway-based approach also creates an
opportunity to explore rational combination strategies that will target not
only the tumor but also the tumor microenvironment and surrounding
immune system.With the new pathway-based approach to education and
knowledge curation, My Cancer Genome hopes that the path(way) less
traveled will positively impact patient care using precision cancer medicine.Acknowledgements
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